She has served as the director of the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University since December 2022.

[1] Sullivan was awarded the 2020 Science, Technology, and Environment Service to America Medal for the development of ansuvimab, an FDA-approved monoclonal antibody for the treatment of Ebola virus disease.

She conducted a dissertation in the laboratory of Joseph Sodroski, where her work demonstrated that primary HIV isolates exhibit resistance to antibody neutralization due to occlusion of the co-receptor binding site on the envelope glycoprotein GP120.

[4][5] Sullivan then pursued postdoctoral training under the guidance of Gary Nabel, studying the mechanisms of Ebola virus pathogenesis and immune protection.

Sullivan’s innovative and specialized work on filovirus immunology is recognized worldwide and has consistently been the source of novel observations that have contributed to critical advancements in the field.